Als-Nielsen
2004
Als-Nielsen B, Gluud LL, Gluud C. Methodological quality and treatment
effects in randomized trials: a review of six empirical studies. 12th
Cochrane Colloquium, Ottawa (Canada), 2004.
Altman
1999
Altman DG, Bland JM. How to randomize. BMJ 1999; 319: 703-704.
Balk
2002
Balk EM, Bonis PAL, Moskowitz H, Schmid CH, Ioannidis JPA, Wang C, Lau
J. Correlation of quality measures with estimates of treatment effect
in meta-analyses of randomized controlled trials. JAMA 2002; 287:
2973-2982.
Bassler
2007
Bassler D, Ferreira-Gonzalez I, Briel M, Cook DJ, Devereaux PJ, Heels-Ansdell
D, Kirpalani H, Meade MO, Montori VM, Rozenberg A, Schunemann HJ, Guyatt
GH. Systematic reviewers neglect bias that results from trials stopped
early for benefit. Journal of Clinical Epidemiology 2007; 60: 869-873.
Bellomo
2000
Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine
in patients with early renal dysfunction: a placebo-controlled randomised
trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical
Trials Group. The Lancet 2000; 356: 2139-2143.
Berger
2003
Berger VW, Ivanova A, Knoll MD. Minimizing predictability while retaining
balance through the use of less restrictive randomization procedures.
Statistics in Medicine 2003; 22: 3017-3028.
Berger
2005
Berger VW. Quantifying the magnitude of baseline covariate imbalances resulting
from selection bias in randomized clinical trials. Biometrical Journal
2005; 47: 119-127.
Berlin
1997
Berlin JA. Does blinding of readers affect the results of meta-analyses?
University of Pennsylvania Meta-analysis Blinding Study Group. The
Lancet 1997; 350: 185-186.
Boutron
2005
Boutron I, Estellat C, Ravaud P. A review of blinding in randomized controlled
trials found results inconsistent and questionable. Journal of Clinical
Epidemiology 2005; 58: 1220-1226.
Boutron
2006
Boutron I, Estellat C, Guittet L, Dechartres A, Sackett DL, Hróbjartsson
A, Ravaud P. Methods of blinding in reports of randomized controlled trials
assessing pharmacologic treatments: a systematic review. PLOS Medicine
2006; 3: 1931-1939.
Brightling
2000
Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord
ID. Sputum eosinophilia and short-term response to prednisolone in chronic
obstructive pulmonary disease: a randomised controlled trial. The Lancet
2000; 356: 1480-1485.
Brown
2005
Brown S, Thorpe H, Hawkins K, Brown J. Minimization: reducing predictability
for multi-centre trials whilst retaining balance within centre. Statistics
in Medicine 2005; 24: 3715-3727.
Chan
2004a
Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence
for selective reporting of outcomes in randomized trials: comparison of
protocols to published articles. JAMA 2004; 291: 2457-2465.
Chan
2004b
Chan AW, Krleža-Jeric K, Schmid I, Altman DG. Outcome reporting bias in
randomized trials funded by the Canadian Institutes of Health Research.
Canadian Medical Association Journal 2004; 171: 735-740.
Chan
2005
Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials
on PubMed: review of publications and survey of authors. BMJ 2005;
330: 753.
Coronary
Drug Project Research Group 1980
Coronary Drug Project Research Group. Influence of adherence to treatment
and response of cholesterol on mortality in the coronary drug project.
New England Journal of Medicine 1980; 303: 1038-1041.
Cuellar
2000
Cuellar GEM, Ruiz AM, Monsalve MCR, Berber A. Six-month treatment of obesity
with sibutramine 15 mg; a double-blind, placebo-controlled monocenter
clinical trial in a Hispanic population. Obesity Research 2000;
8: 71-82.
de
Gaetano 2001
de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular
risk: a randomised trial in general practice. Collaborative Group of the
Primary Prevention Project. The Lancet 2001; 357: 89-95.
Detsky
1992
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbe KA. Incorporating variations
in the quality of individual randomized trials into meta-analysis. Journal
of Clinical Epidemiology 1992; 45: 255-265.
Devereaux
2001
Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, Bhandari
M, Guyatt GH. Physician interpretations and textbook definitions of blinding
terminology in randomized controlled trials. JAMA 2001; 285: 2000-2003.
Emerson
1990
Emerson JD, Burdick E, Hoaglin DC, Mosteller F, Chalmers TC. An empirical
study of the possible relation of treatment differences to quality scores
in controlled randomized clinical trials. Controlled Clinical Trials
1990; 11: 339-352.
Fergusson
2002
Fergusson D, Aaron SD, Guyatt G, Hébert P. Post-randomisation exclusions:
the intention to treat principle and excluding patients from analysis.
BMJ 2002; 325: 652-654.
Fergusson
2004
Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success
of blinding reported in a random sample of randomised, placebo controlled
trials. BMJ 2004; 328: 432.
Furukawa
2007
Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH. Association between
unreported outcomes and effect size estimates in Cochrane meta-analyses.
JAMA 2007; 297: 468-470.
Ghersi
2006
Ghersi D, Clarke M, Simes J. Selective reporting of the primary outcomes
of clinical trials: a follow-up study. 14th Cochrane Colloquium, Dublin
(Ireland), 2006.
Gøtzsche
1996
Gøtzsche PC. Blinding during data analysis and writing of manuscripts.
Controlled Clinical Trials 1996; 17: 285-290.
Gøtzsche
2006
Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW.
Constraints on publication rights in industry-initiated clinical trials.
JAMA 2006; 295: 1645-1646.
Gøtzsche
2007
Gøtzsche PC, Hróbjartsson A, Maric K, Tendal B. Data extraction errors
in meta-analyses that use standardized mean differences. JAMA 2007;
298: 430-437.
Greenland
2001
Greenland S, O'Rourke K. On the bias produced by quality scores in meta-analysis,
and a hierarchical view of proposed solutions. Biostatistics 2001;
2: 463-471.
Haahr
2006
Haahr MT, Hróbjartsson A. Who is blinded in randomised clinical trials?
A study of 200 trials and a survey of authors. Clinical Trials
2006; 3: 360-365.
Hahn
2002
Hahn S, Williamson PR, Hutton JL. Investigation of within-study selective
reporting in clinical research: follow-up of applications submitted to
a local research ethics committee. Journal of Evaluation in Clinical
Practice 2002; 8: 353-359.
Hansson
1999
Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki
K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE.
Effect of angiotensin-converting-enzyme inhibition compared with conventional
therapy on cardiovascular morbidity and mortality in hypertension: the
Captopril Prevention Project (CAPPP) randomised trial. The Lancet
1999; 353: 611-616.
Hill
1990
Hill AB. Memories of the British streptomycin trial in tuberculosis: the
first randomized clinical trial. Controlled Clinical Trials 1990;
11: 77-79.
Hollis
1999
Hollis S, Campbell F. What is meant by intention to treat analysis? Survey
of published randomised controlled trials. BMJ 1999; 319: 670-674.
Hróbjartsson
2007
Hróbjartsson A, Forfang E, Haahr MT, ls-Nielsen B, Brorson S. Blinded trials
taken to the test: an analysis of randomized clinical trials that report
tests for the success of blinding. International Journal of Epidemiology
2007; 36: 654-663.
Hutton
2000
Hutton JL, Williamson PR. Bias in meta-analysis due to outcome variable
selection within studies. Journal of the Royal Statistical Society
Series C 2000; 49: 359-370.
Jadad
1996
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ,
McQuay H. Assessing the quality of reports of randomized clinical trials:
Is blinding necessary? Controlled Clinical Trials 1996; 17: 1-12.
Johansen
2000
Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus
amphotericin B in cancer patients with neutropenia. Cochrane Database
of Systematic Reviews 2000, Issue 3. Art No: CD000969.
Jørgensen
2006
Jørgensen KJ, Johansen HK, Gøtzsche PC. Voriconazole versus amphotericin
B in cancer patients with neutropenia. Cochrane Database of Systematic
Reviews 2006, Issue 1. Art No: CD004707.
Jørgensen
2007
Jørgensen KJ, Johansen HK, Gøtzsche PC. Flaws in design, analysis and interpretation
of Pfizer's antifungal trials of voriconazole and uncritical subsequent
quotations. Trials 2007; 7: 3.
Jüni 1999
Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality
of clinical trials for meta-analysis. JAMA 1999; 282: 1054-1060.
Jüni 2001
Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing
the quality of controlled clinical trials. BMJ 2001; 323: 42-46.
Kjaergard
2001
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies
between large and small randomized trials in meta-analyses. Annals
of Internal Medicine 2001; 135: 982-989.
Lachin
2000
Lachin JM. Statistical considerations in the intent-to-treat principle.
Controlled Clinical Trials 2000; 21: 167-189.
Marshall
2000
Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished
rating scales: a major source of bias in randomised controlled trials
of treatments for schizophrenia. British Journal of Psychiatry
2000; 176:249-52.: 249-252.
Melander
2003
Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased
medicine - selective reporting from studies sponsored by pharmaceutical
industry: review of studies in new drug applications. BMJ 2003;
326: 1171-1173.
Moher
1995
Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the
quality of randomized controlled trials: An annotated bibliography of
scales and checklists. Controlled Clinical Trials 1995; 16: 62-73.
Moher
1996
Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled
trials: Current issues and future directions. International Journal
of Technology Assessment in Health Care 1996; 12: 195-208.
Moher
1998
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen
TP. Does quality of reports of randomised trials affect estimates of intervention
efficacy reported in meta-analyses? The Lancet 1998; 352: 609-613.
Moher
2001a
Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations
for improving the quality of reports of parallel-group randomised trials.
The Lancet 2001; 357: 1191-1194.
Moher
2001b
Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations
for improving the quality of reports of parallel-group randomised trials.
The Lancet 2001; 357: 1191-1194.
Moher
2001c
Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations
for improving the quality of reports of parallel-group randomised trials.
The Lancet 2001; 357: 1191-1194.
Moher
2001d
Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations
for improving the quality of reports of parallel-group randomised trials.
The Lancet 2001; 357: 1191-1194.
Montori
2002
Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA, Guyatt GH. In
the dark: the reporting of blinding status in randomized controlled trials.
Journal of Clinical Epidemiology 2002; 55: 787-790.
Montori
2005
Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti
C, Leung TW, Darling E, Bryant DM, Bucher HC, Schünemann HJ, Meade MO,
Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E,
Guyatt GH. Randomized trials stopped early for benefit: a systematic review.
JAMA 2005; 294: 2203-2209.
Naylor
1997
Naylor CD. Meta-analysis and the meta-epidemiology of clinical research.
BMJ 1997; 315: 617-619.
Newell
1992
Newell DJ. Intention-to-treat analysis: implications for quantitative and
qualitative research. International Journal of Epidemiology 1992;
21: 837-841.
Noseworthy
1994
Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts
R. The impact of blinding on the results of a randomized, placebo-controlled
multiple sclerosis clinical trial. Neurology 1994; 44: 16-20.
Oxman
1993
Oxman AD, Guyatt GH. The science of reviewing research. Annals of the
New York Academy of Sciences 1993; 703: 125-133.
Peto
1999
Peto R. Failure of randomisation by "sealed" envelope. The
Lancet 1999; 354: 73.
Pildal
2007
Pildal J, Hróbjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC.
Impact of allocation concealment on conclusions drawn from meta-analyses
of randomized trials. International Journal of Epidemiology 2007;
36: 847-857.
Porta
2007
Porta N, Bonet C, Cobo E. Discordance between reported intention-to-treat
and per protocol analyses. Journal of Clinical Epidemiology 2007;
60: 663-669.
Rees
2005
Rees JR, Wade TJ, Levy DA, Colford JM, Jr., Hilton JF. Changes in beliefs
identify unblinding in randomized controlled trials: a method to meet
CONSORT guidelines. Contemporary Clinical Trials 2005; 26: 25-37.
Sackett
2007
Sackett DL. Commentary: Measuring the success of blinding in RCTs: don't,
must, can't or needn't? International Journal of Epidemiology 2007;
36: 664-665.
Safer
2002
Safer DJ. Design and reporting modifications in industry-sponsored comparative
psychopharmacology trials. Journal of Nervous and Mental Disease
2002; 190: 583-592.
Schulz
1995a
Schulz KF. Subverting randomization in controlled trials. JAMA 1995;
274: 1456-1458.
Schulz
1995b
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias.
Dimensions of methodological quality associated with estimates of treatment
effects in controlled trials. JAMA 1995; 273: 408-412.
Schulz
1996
Schulz KF, Grimes DA, Altman DG, Hayes RJ. Blinding and exclusions after
allocation in randomised controlled trials: survey of published parallel
group trials in obstetrics and gynaecology. BMJ 1996; 312: 742-744.
Schulz
2002a
Schulz KF, Chalmers I, Altman DG. The landscape and lexicon of blinding
in randomized trials. Annals of Internal Medicine 2002; 136: 254-259.
Schulz
2002b
Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending
against deciphering. The Lancet 2002; 359: 614-618.
Schulz
2002c
Schulz KF, Grimes DA. Generation of allocation sequences in randomised
trials: chance, not choice. The Lancet 2002; 359: 515-519.
Schulz
2002d
Schulz KF, Grimes DA. Unequal group sizes in randomised trials: guarding
against guessing. The Lancet 2002; 359: 966-970.
Schulz
2006
Schulz KF, Grimes DA. The Lancet Handbook of Essential Concepts in Clinical
Research. Edinburgh (UK): Elsevier, 2006.
Senn
1991
Senn S. Baseline comparisons in randomized clinical trials. Statistics
in Medicine 1991; 10: 1157-1159.
Siersma
2007
Siersma V, ls-Nielsen B, Chen W, Hilden J, Gluud LL, Gluud C. Multivariable
modelling for meta-epidemiological assessment of the association between
trial quality and treatment effects estimated in randomized clinical trials.
Statistics in Medicine 2007; 26: 2745-2758.
Smilde
2001
Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef
AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis
progression in familial hypercholesterolaemia (ASAP): a prospective, randomised,
double-blind trial. The Lancet 2001; 357: 577-581.
Spiegelhalter
2003
Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence
and uncertainty in complex cost-effectiveness modelling. Statistics
in Medicine 2003; 22: 3687-3709.
Sterne
2002
Sterne JA, Jüni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical
methods for assessing the influence of study characteristics on treatment
effects in 'meta-epidemiological' research. Statistics in Medicine
2002; 21: 1513-1524.
Tierney
2005
Tierney JF, Stewart LA. Investigating patient exclusion bias in meta-analysis.
International Journal of Epidemiology 2005; 34: 79-87.
Unnebrink
2001
Unnebrink K, Windeler J. Intention-to-treat: methods for dealing with missing
values in clinical trials of progressively deteriorating diseases. Statistics
in Medicine 2001; 20: 3931-3946.
Vickers
2001
Vickers AJ. The use of percentage change from baseline as an outcome in
a controlled trial is statistically inefficient: a simulation study. BMC
Medical Research Methodology 2001; 1: 6.
von
Elm 2006
von Elm E, Röllin A, Blümle A, Senessie C, Low N, Egger M. Selective reporting
of outcomes of drug trials. Comparison of study protocols and pulbished
articles. 14th Cochrane Colloquium, Dublin (Ireland), 2006.
Williamson
2005a
Williamson PR, Gamble C. Identification and impact of outcome selection
bias in meta-analysis. Statistics in Medicine 2005; 24: 1547-1561.
Williamson
2005b
Williamson PR, Gamble C, Altman DG, Hutton JL. Outcome selection bias in
meta-analysis. Statistical Methods in Medical Research 2005; 14:
515-524.
Wood
2004
Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled?
A review of published randomized controlled trials in major medical journals.
Clinical Trials 2004; 1: 368-376.
Wood
2008
Wood L, Egger M, Gluud LL, Schulz K, Jüni P, Altman DG, Gluud C, Martin
RM, Wood AJG, Sterne JAC. Methodological quality and treatment effect
estimates in controlled trials with different interventions and outcomes:
empirical evidence of bias. BMJ (in press, 2008).
Woods
1995
Woods KL. Mega-trials and management of acute myocardial infarction. The
Lancet 1995; 346: 611-614.